Combined First Month Body Weight Loss and Development of Tolerance as Predictors of 6-Month Efficacy of Mazindol in Mild and Moderate Obese Subjects
The weight loss response to anti-obesity drugs is highly variable and poorly understood, which does not allow us to know, in advance, in which subjects the drug will be effective and in which it will not. The objective of this study was to explore the body weight reduction in kilograms in the first...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/11/3211 |
| _version_ | 1811153738658742272 |
|---|---|
| author | Juan Carlos Huerta-Cruz Héctor Isaac Rocha-González Ashuin Kammar-García Samuel Canizales-Quinteros Lina Marcela Barranco-Garduño Juan Gerardo Reyes-García |
| author_facet | Juan Carlos Huerta-Cruz Héctor Isaac Rocha-González Ashuin Kammar-García Samuel Canizales-Quinteros Lina Marcela Barranco-Garduño Juan Gerardo Reyes-García |
| author_sort | Juan Carlos Huerta-Cruz |
| collection | DOAJ |
| description | The weight loss response to anti-obesity drugs is highly variable and poorly understood, which does not allow us to know, in advance, in which subjects the drug will be effective and in which it will not. The objective of this study was to explore the body weight reduction in kilograms in the first month (1mo-BWRkg) and the development of tolerance as predictors of 6-month efficacy for treatment with 1 mg mazindol twice a day. One hundred ninety-six obese subjects were individually or jointly analyzed. Approximately 60% of subjects developed tolerance to mazindol and achieved increasing proportional levels of 6-month efficacy according to 1mo-BWRkg intervals (<1 kg, 1 to <2 kg, 2 to <4 kg and ≥4 kg). Both moT and 1mo-BWRkg were significantly correlated with the mean percentage body weight reduction (BWR%) after 6-months of treatment. The qualitative analysis of both predictors on the progressive efficacy of mazindol was used to classify patients according to expected efficacy (inefficient, slightly effective, partially effective, or fully effective), based on the mean percentage efficacy and the number of subjects reaching a BWR% of <5%, 5 to <10%, 10 to <15% or ≥15%. In conclusion, combined 1mo-BWRkg and moT were early predictors for the progressive efficacy of 6-month mazindol anti-obesity therapy. This finding represents progress in predictive, preventive, and personalized medicine which could serve for estimating the expectations of individual efficacy with the use of the drug. and highlights the basic principle of personalized medicine, “one size does not fit all”. |
| first_indexed | 2024-03-10T01:10:19Z |
| format | Article |
| id | doaj.art-73362b7d5d784fa38eea40041faae3cc |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T01:10:19Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-73362b7d5d784fa38eea40041faae3cc2023-11-23T14:18:44ZengMDPI AGJournal of Clinical Medicine2077-03832022-06-011111321110.3390/jcm11113211Combined First Month Body Weight Loss and Development of Tolerance as Predictors of 6-Month Efficacy of Mazindol in Mild and Moderate Obese SubjectsJuan Carlos Huerta-Cruz0Héctor Isaac Rocha-González1Ashuin Kammar-García2Samuel Canizales-Quinteros3Lina Marcela Barranco-Garduño4Juan Gerardo Reyes-García5Unidad de Investigación en Farmacología, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosio Villegas, Secretaría de Salud, Calzada de Tlalpan 4502, Col. Belisario Domínguez Sección XVI, Tlalpan, Mexico City 14080, MexicoSección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, Col. Casco de Santo Tomas, Miguel Hidalgo, Mexico City 11340, MexicoSección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, Col. Casco de Santo Tomas, Miguel Hidalgo, Mexico City 11340, MexicoFacultad de Química, Universidad Nacional Autónoma de México, Circuito Escolar s/n, Ciudad Universitaria, Coyoacán, Mexico City 04510, MexicoUnidad de Investigación en Farmacología, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosio Villegas, Secretaría de Salud, Calzada de Tlalpan 4502, Col. Belisario Domínguez Sección XVI, Tlalpan, Mexico City 14080, MexicoSección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, Col. Casco de Santo Tomas, Miguel Hidalgo, Mexico City 11340, MexicoThe weight loss response to anti-obesity drugs is highly variable and poorly understood, which does not allow us to know, in advance, in which subjects the drug will be effective and in which it will not. The objective of this study was to explore the body weight reduction in kilograms in the first month (1mo-BWRkg) and the development of tolerance as predictors of 6-month efficacy for treatment with 1 mg mazindol twice a day. One hundred ninety-six obese subjects were individually or jointly analyzed. Approximately 60% of subjects developed tolerance to mazindol and achieved increasing proportional levels of 6-month efficacy according to 1mo-BWRkg intervals (<1 kg, 1 to <2 kg, 2 to <4 kg and ≥4 kg). Both moT and 1mo-BWRkg were significantly correlated with the mean percentage body weight reduction (BWR%) after 6-months of treatment. The qualitative analysis of both predictors on the progressive efficacy of mazindol was used to classify patients according to expected efficacy (inefficient, slightly effective, partially effective, or fully effective), based on the mean percentage efficacy and the number of subjects reaching a BWR% of <5%, 5 to <10%, 10 to <15% or ≥15%. In conclusion, combined 1mo-BWRkg and moT were early predictors for the progressive efficacy of 6-month mazindol anti-obesity therapy. This finding represents progress in predictive, preventive, and personalized medicine which could serve for estimating the expectations of individual efficacy with the use of the drug. and highlights the basic principle of personalized medicine, “one size does not fit all”.https://www.mdpi.com/2077-0383/11/11/3211interindividual variabilitymazindolobesitytoleranceweight loss efficacy |
| spellingShingle | Juan Carlos Huerta-Cruz Héctor Isaac Rocha-González Ashuin Kammar-García Samuel Canizales-Quinteros Lina Marcela Barranco-Garduño Juan Gerardo Reyes-García Combined First Month Body Weight Loss and Development of Tolerance as Predictors of 6-Month Efficacy of Mazindol in Mild and Moderate Obese Subjects Journal of Clinical Medicine interindividual variability mazindol obesity tolerance weight loss efficacy |
| title | Combined First Month Body Weight Loss and Development of Tolerance as Predictors of 6-Month Efficacy of Mazindol in Mild and Moderate Obese Subjects |
| title_full | Combined First Month Body Weight Loss and Development of Tolerance as Predictors of 6-Month Efficacy of Mazindol in Mild and Moderate Obese Subjects |
| title_fullStr | Combined First Month Body Weight Loss and Development of Tolerance as Predictors of 6-Month Efficacy of Mazindol in Mild and Moderate Obese Subjects |
| title_full_unstemmed | Combined First Month Body Weight Loss and Development of Tolerance as Predictors of 6-Month Efficacy of Mazindol in Mild and Moderate Obese Subjects |
| title_short | Combined First Month Body Weight Loss and Development of Tolerance as Predictors of 6-Month Efficacy of Mazindol in Mild and Moderate Obese Subjects |
| title_sort | combined first month body weight loss and development of tolerance as predictors of 6 month efficacy of mazindol in mild and moderate obese subjects |
| topic | interindividual variability mazindol obesity tolerance weight loss efficacy |
| url | https://www.mdpi.com/2077-0383/11/11/3211 |
| work_keys_str_mv | AT juancarloshuertacruz combinedfirstmonthbodyweightlossanddevelopmentoftoleranceaspredictorsof6monthefficacyofmazindolinmildandmoderateobesesubjects AT hectorisaacrochagonzalez combinedfirstmonthbodyweightlossanddevelopmentoftoleranceaspredictorsof6monthefficacyofmazindolinmildandmoderateobesesubjects AT ashuinkammargarcia combinedfirstmonthbodyweightlossanddevelopmentoftoleranceaspredictorsof6monthefficacyofmazindolinmildandmoderateobesesubjects AT samuelcanizalesquinteros combinedfirstmonthbodyweightlossanddevelopmentoftoleranceaspredictorsof6monthefficacyofmazindolinmildandmoderateobesesubjects AT linamarcelabarrancogarduno combinedfirstmonthbodyweightlossanddevelopmentoftoleranceaspredictorsof6monthefficacyofmazindolinmildandmoderateobesesubjects AT juangerardoreyesgarcia combinedfirstmonthbodyweightlossanddevelopmentoftoleranceaspredictorsof6monthefficacyofmazindolinmildandmoderateobesesubjects |